BOSTON--(BUSINESS WIRE)--Anagenex, a pioneering drug discovery company pairing large-scale data generation with proprietary artificial intelligence (AI) to discover the next generation of small molecule medicines, today announced the appointment of Robert Forrester as Executive Chairman of its Board of Directors. The company also welcomed Isaac Ro to its Board of Directors.
“Robert and Isaac’s extensive experience as life science executives is invaluable to the Anagenex team as we realize our vision of becoming a vertically integrated small molecule drug discovery company,” said Nicolas Tilmans, CEO of Anagenex. “Our unique AI driven platform has already powered two lead programs with novel chemical matter and continues to scale. Robert and Isaac add considerable leadership experience with business development and finance as we further expand our platform to grow our pipeline, develop partnerships and ultimately deliver more drugs to patients faster.”
Robert Forrester is a life sciences executive and entrepreneur with more than 20 years of experience leading both public and private companies including EQRx, Verastem Oncology, Forma Therapeutics, CombinatoRx and Coley (acquired by Pfizer). He has co-founded 8 companies including IDRx and EQRx. Earlier in his career, Robert worked for several investment banks undertaking M&A and finance transactions and served as a managing director of the Proprietary Investment Group at MeesPierson investing in life science companies. Robert holds an LL.B. from Bristol University, UK.
Isaac Ro has extensive experience as an investor, board member and operator having navigated multiple financings, M&A transactions and exits. Isaac is currently a Partner at Catalio Capital Management, LP, where he helps lead the private investments team. He previously served as Executive Chairman of Haystack Oncology (sold to Quest Diagnostics), Chief Financial Officer of Sema4 (took public NASDAQ: WGS, and acquired GeneDx), and Chief Financial Officer of Thrive Earlier Detection (sold to Exact Sciences). Previously, he was an equity research analyst at Goldman Sachs and Leerink Partners. Isaac holds a B.A. in History from Middlebury College.
About Anagenex
Anagenex is pairing high quality, large-scale data generation with AI to discover the next generation of small molecule medicines. Driven by over 100 billion proprietary measurements, Anagenex's platform leverages AI to design and synthesize hundreds of millions of target-specific compounds for testing in two weeks, creating a virtuous cycle between real lab experiments and computational tools. Led by a team of highly experienced scientists and engineers, the company’s pipeline is focused on synthetic lethal oncology. Learn more about us at www.anagenex.com or connect with us on LinkedIn.
